Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. NewAmsterdam Pharma Co NV's annualized net income for the quarter that ended in Jun. 2026 was $-256.54 Mil. NewAmsterdam Pharma Co NV's average shareholder tangible equity for the quarter that ended in Jun. 2026 was $647.96 Mil. Therefore, NewAmsterdam Pharma Co NV's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was -39.59%.
The historical rank and industry rank for NewAmsterdam Pharma Co NV's Return-on-Tangible-Equity or its related term are showing as below:
NAMS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -160.79 Med: -46.23 Max: -9.31
Current: -37.24
During the past 6 years, NewAmsterdam Pharma Co NV's highest Return-on-Tangible-Equity was -9.31%. The lowest was -160.79%. And the median was -46.23%.
NAMS's Return-on-Tangible-Equity is ranked better than 57.95% of 1201
companies
in the Biotechnology industry
Industry Median: -42.68
vs NAMS: -37.24
NewAmsterdam Pharma Co NV (NAS:NAMS) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
NewAmsterdam Pharma Co NV Return-on-Tangible-Equity Related Terms
NewAmsterdam Pharma Co NV Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for NewAmsterdam Pharma Co NV's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NewAmsterdam Pharma Co NV Return-on-Tangible-Equity Chart
NAMS vs ARQT, IDYA, ALMS: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewAmsterdam Pharma Co NV Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where NewAmsterdam Pharma Co NV's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -39.59% mean?
NewAmsterdam Pharma Co NV (NAMS) has a Return-on-Tangible-Equity of -39.59% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NewAmsterdam Pharma Co NV and its competitors. According to the industry distribution chart, NewAmsterdam Pharma Co NV ranks #505 out of 1201 companies in the Biotechnology industry, placing it in the top 42%.
Is NewAmsterdam Pharma Co NV's Return-on-Tangible-Equity too high?
NewAmsterdam Pharma Co NV's current Return-on-Tangible-Equity is -39.59%. Based on the distribution chart, NewAmsterdam Pharma Co NV ranks #505 out of 1201 companies in the Biotechnology industry, which is above the industry midpoint. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's Return-on-Tangible-Equity compare to ARQT and IDYA?
According to the Biotechnology industry distribution chart, NewAmsterdam Pharma Co NV ranks #505 out of 1201 companies for Return-on-Tangible-Equity. This puts NewAmsterdam Pharma Co NV in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NewAmsterdam Pharma Co NV and its competitors. NewAmsterdam Pharma Co NV's current Return-on-Tangible-Equity is -39.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.42, compared to a current price of $27.96 — trading 168.3% above its estimated fair value. The current Return-on-Tangible-Equity is -39.59%. NewAmsterdam Pharma Co NV's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current Return-on-Tangible-Equity is -39.59% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued.
The current stock price of $27.96 is trading 168.3% above its estimated GF Value™ of $10.42.
GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.
Key valuation signals for NAMS:
Return-on-Tangible-Equity: -39.59%
GF Value™: $10.42 vs. price of $27.96 (168.3% above fair value)
No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
45GF Score
Get the complete analysis for NAMS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAMS has been successfully added to your 
